SAN DIEGO--(BUSINESS WIRE)--Sequenom, Inc. (NASDAQ:SQNM), a leading provider of genetic analysis solutions, today announced results of a large, multicenter retrospective study from the Children’s Hospital Oakland Research Institute and the University of Minnesota Cancer Center showing that donors with more stimulatory natural killer cell immunoglobulin-like receptor (KIR) haplotypes result in significantly improved treatment outcome in patients with acute myelogenous leukemia (AML) who received hematopoietic cell transplantation (HCT) therapy. The complete results from the study are published in Blood (Volume 113, Number 3), the journal of the American Society of Hematology.
